Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma

Phase II Study of ZK 219477 in Patients With Recurrent Glioblastoma

RATIONALE: Drugs used in chemotherapy, such as epothilone ZK-219477, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well epothilone ZK-219477 works in treating patients with recurrent glioblastoma.

Study Overview

• Status: Completed
• Conditions: Brain and Central Nervous System Tumors
• Intervention / Treatment: Genetic: gene expression analysis; Other: pharmacological study; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: fluorescence in situ hybridization; Drug: sagopilone

Detailed Description

OBJECTIVES:

Primary

• Assess the therapeutic activity of epothilone ZK-219477 in patients with recurrent glioblastoma.

Secondary

• Determine the safety profile, mechanism of action, and pharmacokinetics of this drug in these patients.
• Gather information about the biological characteristics of the patients' tumor that may provide information on response or resistance to this drug.

OUTLINE: This is a nonrandomized, open-label, multicenter study.

Patients receive epothilone ZK-219477 IV over 3 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline for biomarker analysis and for comparison of genetic alterations in tumor tissue with germline DNA. Blood samples are also collected periodically during course 1 for pharmacokinetic studies. Tumor tissue obtained at diagnosis, and possibly recurrence, is used for immunohistochemical analyses for biomarkers. Fluorescent in situ hybridization (FISH) is used to detect genetic alterations and gene expression.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Phase 2

Contacts and Locations

Study Locations

• Switzerland
  • Lausanne, Switzerland, CH-1011
    • Centre Hospitalier Universitaire Vaudois

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Histologically confirmed glioblastoma

  • Presence of oligodendroglial elements allowed provided they make up < 25% of tumor
• Measurable disease, defined as ≥ 1 bidimensionally measurable target lesion with a largest diameter of ≥ 2 cm by MRI within the past 2 weeks

• Recurrent disease

  • Documented by MRI after failing prior therapy (usually standard radiotherapy with concurrent and maintenance temozolomide)
  • Subsequent histologic confirmation of recurrence required for patients who received prior high-dose radiotherapy (> 65 Gy), stereotactic radiosurgery, or internal radiotherapy
• Multifocal disease that is not amenable to radiotherapy allowed provided the patient received no more than 1 line of prior chemotherapy

PATIENT CHARACTERISTICS:

• WHO performance status 0-2
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin < 1.5 times upper limit of normal (ULN)
• AST and ALT < 2.5 times ULN
• Alkaline phosphatase < 2.5 times ULN
• Creatinine < 1.5 times ULN
• Clinically normal cardiac function

• No ischemic heart disease within the past 12 months

  • Stable ischemic heart disease (e.g., treated angina that is stable under appropriate therapy) allowed
• No New York Heart Association class III or IV cardiac insufficiency
• No unstable angina
• No arrhythmia
• No psychological, familial, sociological, or geographical factors that would preclude study compliance
• No other malignancy except cone-biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer
• Not pregnant or nursing
• Negative pregnancy test
• Fertile female patients must use effective contraception during and for 3 months after completion of study treatment
• Fertile male patients must use effective contraception during and for 6 months after completion of study treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
• More than 3 months since prior radiotherapy to the brain

• More than 3 months since prior surgery for recurrent primary brain tumor unless 1 of the following criteria are met:

  • Measurable residual disease documented by immediate (within 72 hours) postoperative imaging
  • Evidence of a progressive and measurable target lesion found at postoperative follow-up
  • Presence of a second measurable target lesion outside the surgical area
• Prior adjuvant temozolomide as first-line therapy allowed

• No prior chemotherapy for recurrent glioblastoma

  • One prior chemotherapy regimen given as adjuvant therapy allowed
• Concurrent corticosteroids allowed provided dose is stable or decreasing for ≥ 1 week
• No concurrent phenytoin, carbamazepine, or phenobarbital
• No concurrent Hypericum perforatum (St. John's wort)

• No concurrent enzyme-inducing antiepileptic drugs (EIAEDs)

  • Patients on EIAEDs should have been switched to non-EIAEDs with a wash-out period of ≥ 1 month
• No other concurrent anticancer agents (except alternative or homeopathic medicine)
• No other concurrent investigational treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Treatment success (complete or partial response or a progression-free survival at 6 months)

Secondary Outcome Measures

Outcome Measure
Objective response
Toxicity
Duration of response
Progression-free survival at 6 months
Overall survival at 6 and 12 months

Collaborators and Investigators

• Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Publications and helpful links

General Publications

• Stupp R, Tosoni A, Bromberg JEC, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol. 2011 Sep;22(9):2144-2149. doi: 10.1093/annonc/mdq729. Epub 2011 Feb 14.
• Stupp R, Tosoni W, Taal W, et al.: Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: initial report of the EORTC study 26061. [Abstract] J Clin Oncol 26 (Suppl 15): A-2015, 2008.

Study record dates

Study Major Dates

• Study Start: December 1, 2006
• Primary Completion (Actual): August 1, 2007

Study Registration Dates

• First Submitted: January 16, 2007
• First Submitted That Met QC Criteria: January 16, 2007
• First Posted (Estimate): January 18, 2007

Study Record Updates

• Last Update Posted (Estimate): September 24, 2012
• Last Update Submitted That Met QC Criteria: September 20, 2012
• Last Verified: September 1, 2012

More Information

Terms related to this study

• Keywords: adult glioblastoma; adult giant cell glioblastoma; adult gliosarcoma; recurrent adult brain tumor
• Additional Relevant MeSH Terms: Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioblastoma; Nervous System Neoplasms; Central Nervous System Neoplasms; Antineoplastic Agents; Sagopilone
• Other Study ID Numbers: EORTC-26061; EUDRACT-2006-001659-37; SPRI-EORTC-26061